Back to top

Increased Earnings Estimates Seen for Chemours (CC): Can It Move Higher?

Read MoreHide Full Article

The Chemours Company (CC - Free Report) , a provider of performance chemicals, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Chemours could be a solid choice for investors.

Current Quarter Estimates for CC

In the past 30 days, 1 estimate has gone higher for Chemours while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 26 cents a share 30 days ago, to 30 cents today, a move of 15.4%.

Current Year Estimates for CC

Meanwhile, Chemours’ current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 77 cents per share 30 days ago to 85 cents per share today, an increase of 10.4%.

CHEMOURS COMPNY Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 18.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Chemours Company (The) (CC) - free report >>

More from Zacks Tale of the Tape

You May Like